-
subsidiaries Genmab B.V. in Utrecht, the Netherlands,
Genmab U.S., Inc. in Princeton, New Jersey, US, and
Genmab K.K. in Tokyo, ****an.
Genmab is a dual-listed...
- cells.
Daratumumab was
originally developed by
Genmab, but it is now
being jointly developed by
Genmab along with the
Johnson &
Johnson subsidiary Janssen...
-
leukemia (CLL) in the
United States. It is sold by
Novartis under license from
Genmab. The most
common side
effects for
ofatumumab (Kesimpta)
include upper respiratory...
- co-developed with
Astellas Pharma,
tisotumab vedotin,
being co-developed with
Genmab, SGN-LIV1A, an ADC
targeting LIV-1, and
several immuno-oncology
agents in...
-
following the last dose. It is a
human monoclonal antibody developed by
Genmab and
Roche for
tumour treatment but was
later researched by
River Vision...
-
Humatin (Pfizer)
Humatrope (Eli
Lilly and Company) HuMax-CD4 (
Genmab) HuMax-EGFR (
Genmab)
Humegon (Organon International)
Humorsol Humulin (Eli
Lilly and...
- CD20-directed CD3 T-cell engager.
Epcoritamab was co-developed by
AbbVie and
Genmab.
Epcoritamab was
approved for
medical use in the
United States in May 2023...
-
Galenika (1945– )
Gedeon Richter (1901– )
Genentech (1976– )
General (1984– )
Genmab (1999– )
Genset (1989– )
Giaconda (2004– )
Gilead (1987– )
Glatt group (1954–...
-
companies Denmark Ambu
Carlsberg Chr.
Hansen Coloplast Danske Bank DSV
Genmab GN
Store Nord Novo
Nordisk Ørsted
Vestas Wind
Systems Finland Fortum KONE...
- epcoritamab, a blood-cancer
therapy under development in
partnership with
Genmab. The name "AbbVie" is
derived from a
combination of "Abbott", the name of...
